- Motif Bio has secured up to $20m in debt financing with Hercules Capital to fund preparation activities ahead of the US launch of iclaprim in 2019.

The first tranche of $15m will be drawn down immediately, with the remaining $5m available upon the achievement of certain milestones anticipated in 2018, the company said.

At 9:18am: [LON:MTFB] Motif Bio Plc Ord 1p share price was -0.62p at 36.13p

Story provided by